Heidi W.
- Country
- Germany
- Department
- Medizinische Klinik 5; Hämatologie und Internistische Onkologie
Research Overview
- Safety Evaluation of CC-93269 in Patients with Relapsed and Refractory Multiple Myeloma
- Efficacy of Venetoclax and Azacitidine Versus Standard Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with NPM1 Mutations
- Sequential Administration of Gilteritinib, Venetoclax, and Azacitidine in Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia Ineligible for Intensive Therapy
Data & Insights
Has run more than one trial at 22 of 154 partner sites.
Specializations
Hematologic Oncology
This investigator specializes in the treatment of multiple myeloma, with particular emphasis on addressing cases that have shown resistance to previous therapies. Their research focuses on investigating novel therapeutic approaches for relapsed and refractory multiple myeloma (RRMM).
- Blood Cancer Treatment
- Multiple Myeloma Management
- Refractory Disease Therapy
The investigator's work encompasses innovative antibody-based treatments for patients whose condition has progressed after previous therapeutic interventions.
Immunotherapy Research
Their expertise extends to the development and implementation of antibody-based treatments in hematologic malignancies. The investigator's work focuses on evaluating novel immunotherapeutic approaches for patients with advanced blood cancers.
- Antibody Therapeutics
- Targeted Therapy
- Treatment Resistance
The research involves exploring innovative immunological approaches for patients who have experienced disease progression following standard treatments.
Treatment Resistance Studies
The investigator concentrates on addressing treatment-resistant blood cancers, particularly in cases where conventional therapies have proven ineffective. Their work involves evaluating new therapeutic strategies for patients with limited treatment options.
- Drug Resistance Mechanisms
- Alternative Treatment Approaches
- Therapy Innovation
Their research aims to provide therapeutic solutions for patients who have developed resistance to standard treatment protocols.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.